University of Texas System

Other

Kansas State University Research Foundation

Allan R Brasier

Thomas G Wood

Bing Tian

Hyunsu Ju

Jia Zhou

David G Gorenstein

Daniel A Ventura

David J King

Steven G Widen

Yingxin Zhao

Heidi Spratt

Adrian Recinos

David H Walker

Stefan H Bossmann

Massoud Motamedi

Deryl L Troyer

Rong C Fang

Nisha Jain Garg

Zhiqing Liu

Tadeusz Kochel

Roberto P Garofalo

Antonella Casola

Nikos Vasilakis

Sanjiv Sur

Christopher T Culbertson

Haiying Chen

Yuanfen Wei

Tao Hai

Gary D Boetticher

William J Calhoun

Josefina Nores Garcia

Ernesto E T Marquez

Erik Rytting

Eduardo Nascimento

Laura H V G Gil

Marli Tenorio

Certain embodiments are directed to detection methods and methods of identifying detection targets for sensitive and specific laboratory tests to diagnose and monitor rickettsial infections during the earliest stages of the disease and to assess the degree of illness.

Methods and compositions for diagnosis of rickettsia infection

Methods and devices for microfluidic detection of a biological maker in a biospecimen collected from a subject are disclosed. The microfluidic devices include nanoparticle-based nanosensors comprising supramolecular recognition sequences, protease consensus sequences, post-translationally modifiable sequences, or sterically hindered benzylether bonds for specific interaction with a biological marker. Also disclosed are particular nanosensors for detecting cytokines, and other proteins based upon supramolecular recognition without chemical modification or enzymatic cleavage.

Nanosensors and methods for detection of biological markers

Certain embodiments are directed to methods of using BRD4 inhibitors for treating IgE-mediated diseases.

BRD4 inhibitor treatment of IgE-mediated diseases

Certain embodiments are directed to small molecule selective inhibitors of the BRD4 bromodomain. Compounds described herein can be used to modulate the bronchiolar NFkB-BRD4 axis, which plays a role in acute neutrophilic response to viral molecular patterns. Compounds described herein can be developed as preventive and therapeutic agents for various human diseases and conditions.

Inhibitors of bromodomain-containing protein 4 (BRD4)

Certain embodiments are directed to methods of treating chronic lung diseases in a subject comprising administering to a subject diagnosed with, exhibiting symptoms of, or at risk of developing a chronic lung disease a therapeutically effective amount of a BRD4 inhibitor or a CDK9 inhibitor to the subject.

Methods for treating epithelian mesenchymal transition related diseases

The present invention provides compositions and methods for detecting, analyzing, and identifying biomolecules used to diagnose patient with risk of DHF. More particularly, the invention provides plasma biomarkers including complement factor D to complement factor H (FactorD/FactorH) ratio and levels of one or more of IL2, desmoplakin, and high molecular weight albumin, which are used to detect risk of developing DHF.

Method and biomarkers for the detection of dengue hemorrhagic fever

DNA aptamers are high affinity ligands selected by genetic enrichment techniques to bind to specific protein targets. Because these represent chemically stable and reproducible molecules, they have application as affinity reagents and/or therapeutic drugs to affect the target protein's actions. NF-kB is an important mediator of the innate immune response and mediator of tissue inflammation. Although RNA and double stranded DNA aptamers have been identified to bind to the NF-kB family of proteins, the present invention represents the first identification of single stranded DNA aptamers that recognize NFkB RelA. The aptamers disclosed herein bind to several distinct regions of RelA and may be useful to antagonize the DNA binding of RelA as an inhibitor of cellular inflammation, visualize the location or amount of RelA in tissues from pathological conditions, or to quantitatively measure the activated state of RelA by affinity binding.

Single stranded DNA aptamers binding NF-kB/RelA

Certain embodiments include methods for assessing a subject having a trypanosome infection for the presence or absence of indications of cardiomyopathy.

Biomarkers for chagas disease related cardiomyopathy

The present invention provides methods for detecting, analyzing, and identifying biomolecules used to identifying patient with dengue-like symptom who are at risk of DHF. The inventive method comprises detecting in a sample from a subject dengue infected patient one or more biomarkers selected from the group consisting of IL-10, fibrinogen, C4A, immunoglobulin, tropomyosin, and three isoforms of albumin, and which are used in a predictive MARS model to detect patients with risk of developing DHF.

Methods and biomarkers for the detection of dengue hemorrhagic fever

Single stranded DNA aptamers binding NF-&#x3ba;B/RelA

The present invention discloses a method for classifying individuals into those who have airway hyperreactvitiy and those with asthma based on cytokine expression patterns. It is contemplated that such a method will enable rapid identification of individuals requiring intensive treatment for asthma, thereby reducing morbidity and improving quality of life for those affected.

Molecular phenotyping of severe asthma

Disclosed are isolated IKK&#x3b3;&#x394;; isolated nucleic acid molecules encoding IKK&#x3b3;&#x394;; expression vectors and cells which contain such nucleic acid molecules; oligonucleotides which are complementary to at least a portion of nucleic acid molecules encoding IKK&#x3b3;&#x394; but which are not complementary to any portion of nucleic acid molecules encoding wild type IKK&#x3b3;; antibodies which are specific for IKK&#x3b3;&#x394;; DNA and RNA oligomers, optionally in labeled or enzymatically active form, which are capable of selectively hybridizing to nucleic acid molecules encoding IKK&#x3b3;&#x394;; and DNA and RNA oligomers, optionally in labeled or enzymatically active form, which are capable of selectively hybridizing to nucleic acid molecules encoding IKK&#x3b3;&#x394; but which do not hybridize with nucleic acid molecules encoding wild type IKK&#x3b3;. Methods for using these materials to inhibit formation of IKK&#x3b3;&#x394;-containing IKK, to inhibit NF-&#x3ba;B activation, and to treat or prevent inflammation are also disclosed.

IKK gamma gene products and methods for making and using same

A random combinatorial selection method is disclosed for the construction of oligonucleotide aptamers in which nuclease resistance is conferred by the inclusion of modified nucleotides. The modified nucleotides are incorporated during PCR amplification to form achiral modified oligonucleotides. Thio-substituted aptamers are provided that bind tightly to the nuclear factor for human IL6 (NF-IL6).

Combinatorial selection of oligonucleotide aptamers

The present invention relates to a method of treating lung inflammation in a subject which includes administering butylated hydroxyanisol to the subject in an amount effective to treat lung inflammation. The invention also relates to methods of inhibiting interferon regulatory factor activation in a subject and in an alveolar cell. Another aspect of the invention relates to an assay.

Methods of treating lung inflammation

Growing community of inventors

Austin, TX, United States of America

Allan R Brasier